#Brazil #São Paulo #MGI Tech #genomic testing #Oncoclínicas

MGI Tech Partners with Oncoclínicas for Genomic Innovation

MGI Tech Co., Ltd. has recently announced a significant partnership with OncoclínicasCo through OC Medicina de Precisão, focusing on the integration of cutting-edge genomic technologies into cancer care. This collaboration aims to expand access to state-of-the-art genomic tests, thereby enhancing diagnostic capabilities in oncology across Brazil.

With the increasing prevalence of cancer in Brazil, the necessity for advanced diagnostic methods is more pressing than ever. Recent findings from the Federal University of São Paulo (UNIFESP) reveal that cancer deaths have surpassed those attributed to cardiovascular diseases in 727 Brazilian municipalities. This alarming trend, documented in The Lancet Regional Health – Americas, underscores the urgent need for proactive detection and treatment modalities which can lead to improved clinical outcomes.

The strategic objectives of this partnership focus on developing technological solutions that can streamline diagnostic processes, reduce associated costs, and facilitate quicker therapeutic decisions. Such advancements are expected to contribute greatly to an equitable healthcare system that prioritizes both patient welfare and professional needs.

Carlos Carpio, MGI's Senior Commercial Director for Latin America and General Manager for Brazil, emphasized the transformative power of genomics in cancer care. He stated, "This partnership marks a major advancement in oncology within Brazil, fostering greater awareness among the medical community and patients alike regarding the benefits of oncogenetics. The collaboration is spearheading the push for precise and personalized medicine, making advanced technologies more accessible and expanding genetic diagnostic capabilities."

Fernanda Koyama, Manager of Genomics and RD at OncoclínicasCo, also highlighted the partnership's potential for elevating laboratory operations in genomic medicine. She noted, "By leveraging state-of-the-art technologies and expert support, our laboratories will enhance productivity and reduce operational costs while generating higher-quality data. This collaborative effort empowers our facilities to deliver faster and more accurate diagnostic results, directly benefiting patient care and expediting the development of personalized treatment plans."

Additionally, OncoclínicasCo is now equipped with the latest medium-throughput DNBSEQ-G400 genomic sequencer, utilizing MGI's DNBSEQ technology. This advanced equipment allows rapid sequencing processes, enabling the identification of genetic predispositions to cancer and specific gene mutations that can dictate effective treatment strategies through comprehensive tumor profiling.

According to OncoclínicasCo, the Genomics department processed approximately 1,000 samples monthly in 2024, culminating in a total of 12,000 samples for the year. Notably, 60% of these focused on germline panels for cancer syndrome diagnosis while the remaining targeted somatic panels aimed at therapeutic decisions based on genomic markers.

Rodrigo Alvarenga, Operations Executive at OncoclínicasCo, outlined the organization's commitment to continuously enhancing process effectiveness and adopting new technologies. "Over the past two years, we have made substantial investments aimed at improving efficiencies. This is crucial for serving an increasing number of private patients and for solidifying partnerships with pharmaceutical companies. We aspire to be the premier choice for health insurers in precision medicine, thereby broadening public access to advanced medical solutions and ensuring the sustainability of our healthcare ecosystem."

Expanding Operations in Brazil

The surge in genomic research throughout Latin America has led to a notable demand for Next-Generation Sequencing tests for cancer diagnosis. MGI Tech, active in over 100 countries worldwide, established a Customer Experience Center in São Paulo in 2024 to support clinical laboratories and healthcare institutions. This center facilitates demonstrations, training sessions, and local support for MGI technologies to enhance users' understanding and operational capacities.

In the same year, MGI also forged a strategic agreement with Dasa and the Sabin Group to amplify health diagnostics through genetic sequencing innovations in Brazil. This partnership seeks to introduce advanced testing technologies for cancer diagnosis and rare diseases while further propelling personalized medical practices throughout the region.

With this collaboration, MGI Tech and OncoclínicasCo are set to profoundly impact oncology in Brazil, paving the way for the future of precision medicine in the face of rising cancer challenges.